Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management - Episode 19

Balancing Treatment Efficacy with Toxicity in Metastatic RCC

May 11, 2022

David Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, Chung-Han Lee, MD, PhD

David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.

EP. 1: Trends in RCC Incidence

EP. 2: RCC Histologies

EP. 3: Risk Models and Prognostic Factors

EP. 4: Metastatic RCC: Prognosis and Recent Advances in Care

EP. 5: Biomarker Testing in RCC: Current Approaches

EP. 6: Biomarker Testing: Methodologies, Sample Types, and Emerging Data

EP. 7: Prognostic Value of Biomarkers in RCC

EP. 8: The Role of Genetic Mutations in Prognosis and Decision-Making

EP. 9: Comparison of Older First-Line, Single-Agent Therapies

EP. 10: Newer First-Line Combination Therapy Options

EP. 11: Evolution of Combination Therapy As The Standard of Care

EP. 12: Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

EP. 13: Safety and Efficacy Data: The CheckMate 214 Trial

EP. 14: Safety and Efficacy Data: The JAVELIN Renal 101 Trial

EP. 15: Safety and Efficacy Data: The KEYNOTE-426 Trial

EP. 16: Safety and Efficacy Data: The CheckMate 9ER Trial

EP. 17: Safety and Efficacy Data: The CLEAR Trial

EP. 18: Common Adverse Events with Single-Agent or Combination Therapy

EP. 19: Balancing Treatment Efficacy with Toxicity in Metastatic RCC

EP. 20: Strategies for Prevention and Management of Adverse Events

EP. 21: Patient-Specific Factors Impacting Treatment Choices in RCC

EP. 22: Considerations for Patient-Focused, Shared Decision-Making in RCC